The prevention of the maternal manifestations of pre-eclampsia by intensive antihypertensive treatment.
The purpose of the study was to determine if reduction of pregnancy hypertension to normal prevented the clinical maternal manifestations of pre-eclampsia. Thirty-six women with hypertension, but without proteinuria, were allotted at random to a test group of 17 who received intensive treatment, and a control group of 19 who were managed according to routine methods by hospital staff unconnected with the study. The development of proteinuria was chosen as an indicator of pre-eclampsia. Proteinuria developed significantly more often in the control group (in six of the 19 women) than in the test group (in one of the 17 women).
Blake
S
S
National Maternity Hospital, Dublin.
MacDonald
D
D
D000328:Adult; D001262:Atenolol / Q000627:therapeutic use; D001539:Bendroflumethiazide / Q000627:therapeutic use; D001724:Birth Weight; D004359:Drug Therapy, Combination; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005313:Fetal Death; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007231:Infant, Newborn; D008750:Methyldopa / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000150:complications / Q000517:prevention & control*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011507:Proteinuria / Q000209:etiology
D001262:Atenolol; D008750:Methyldopa; D001539:Bendroflumethiazide